Prosthesis Versus Osteosynthesis in Proximal Tibia Fractures
Launched by CENTRAL FINLAND HOSPITAL DISTRICT · May 30, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different ways to treat a specific type of knee fracture called an intra-articular proximal tibia fracture in patients over 65 years old. The researchers want to find out how well these two treatments work in terms of knee function and pain one year after the injury. The two treatment options being compared are osteosynthesis, which involves using a locking plate to stabilize the fracture, and primary total knee replacement (TKR), where the damaged joint is entirely replaced with an artificial one.
To participate in this study, patients need to have a specific type of fracture and must be willing to consider both treatment options. Some key factors that may make someone eligible include having a fracture that affects the joint with a certain level of severity, having an intact patellar tendon (the tendon connecting the kneecap to the shinbone), and being able to cooperate during the study. However, individuals with severe osteoarthritis, multiple fractures, or other serious health issues may not qualify. If you decide to join the trial, you can expect to be monitored and assessed for knee function and pain over the course of a year, helping researchers determine which treatment might be better for older patients with this type of injury.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute intra-articular proximal tibia fracture with impression of the joint cartilage (Schatzker grades II to VI)
- • Impression of tibial plateau min 2 mm
- • Intact patellar tendon
- • The patient accepts both treatment options (osteosynthesis and arthroplasty)
- Exclusion Criteria:
- • Not voluntary
- • Previous arthroplasty of the knee
- • Previous fracture affecting the knee joint
- • Inability to co-operate
- • Not independent (institutionalized living before fracture)
- • Severe osteoarthritis (Kellgren-Lawrence grade 4)
- • Open fracture (Gustilo grade 2 or over)
- • Progressive metastatic malign disease
- • Multiple fractures requiring operative treatment
- • Severe soft tissue injury around the knee (Tscherne classification grade 3)
- • Avulsion fracture of the patellar tendon or concomitant patellar tendon tear
- • Inability to walk before fracture
- • Severe medical comorbidities
- • Body Mass Index over 40
- • Unacceptably high risk of surgery due to severe medical comorbidities
- • Significant arterial or nerve trauma
- • Severe substance abuse
About Central Finland Hospital District
Central Finland Hospital District is a leading healthcare organization dedicated to advancing medical research and improving patient care through innovative clinical trials. Committed to the highest standards of ethical practice and scientific rigor, the district collaborates with a network of healthcare professionals and researchers to facilitate cutting-edge studies across various medical fields. With a focus on enhancing treatment outcomes and fostering health advancements, Central Finland Hospital District plays a pivotal role in translating research findings into practical applications that benefit the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oulu, , Finland
Kuopio, , Finland
Seinäjoki, , Finland
Tampere, , Finland
Turku, , Finland
Lahti, , Finland
Jyväskylä, , Finland
Tampere, , Finland
Patients applied
Trial Officials
Juha Paloneva, MD, PhD
Principal Investigator
Central Finland Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials